Trial Locations

Facility	City	State	Country	Status	Distance

Back to Search

HER2 Testing and Treatment for High-grade Ovarian Cancer

Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary

Recruiting Observational Study

Exploring HER2 Positive Diagnostic Criteria in High-grade Serous Ovarian Cancer Observing the Effectiveness of Targeted HER2 ADC Drugs

No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.

At a Glance

Age: 18 – 75
Sex: Female
Study type: Observational
Participants needed: 144 (estimated)
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Other

Who this trial is looking for

This trial is looking for women with high-grade serous ovarian cancer. By participating, you will help researchers study how HER2 detection methods can guide treatment with specific targeted drugs.

Are You a Good Fit for This Trial?

You may be able to join if

I have been diagnosed with high-grade serous adenocarcinoma of the ovary.
My cancer is at FIGO stage II or above.
I have complete clinical and follow-up data.
I have pathological slices stored from within the last 5 years.

You may not be able to join if

My pathological slices failed quality control.
I have incomplete follow-up data.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility

About This Trial

Ovarian cancer is the most lethal gynecological malignancy, and 70% of ovarian cancer patients are diagnosed late at the time of new diagnosis. Even after systematic treatment, 75% of patients still relapse within 3 years and 70% die within 5 years. The survival prognosis of platinum resistant and refractory ovarian cancer populations is currently an urgent issue that needs attention. Antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) significantly improved the survival prognosis of patients with multiple solid tumors, such as breast cancer, gastric cancer, colorectal cancer, etc. Anti HER2 drugs have been a research hotspot in the treatment of advanced ovarian cancer in recent years. The expression status of HER2 has a decisive impact on the efficacy of ADC drugs targeting HER2. However, there is still a lack of large-scale data on HER2 expression rate in ovarian cancer patients, and there is no clear detection standard to guide clinical practice, which restricts the application of anti-HER2 ADC drugs in ovarian cancer. To address this critical clinical issue, we initiated this study, which was divided into two parts: ① Retrospective study: Using the existing 144 samples of high-grade serous epithelial ovarian cancer(HGSOC) in our center, we used immunohistochemistry (IHC), DNA in situ hybridization (ISH), and second-generation sequencing (NGS) techniques to detect HER2 status, clarify the relationship between HER2 expression rate and patient survival outcomes, and preliminarily explore the best detection techniques and corresponding positive judgment thresholds for evaluating HER2 status in HGSOC; ② Real world observational study: To verify the predictive value of the positive judgment threshold determined in ① for efficacy in 20 ovarian cancer patients who received HER2 targeted ADC drugs due to platinum resistance/platinum refractory and no other effective treatment options in clinical practice. The aim of this project is to explore for the first time a reliable and feasible method for assessing the expression status of HER2 in patients with epithelial ovarian cancer, in order to provide a basis for subsequent evaluation of targeted HER2 therapy.

Trial Locations

Loading trial locations…

Eligibility Criteria

Inclusion Criteria: 1. Pathological type: high-grade serous adenocarcinoma of the ovary 2. Pathological slices stored within 5 years 3. FIGO stage II or above 4. Complete clinical and follow-up data Exclusion Criteria: 1. Slice quality control failure 2. Incomplete follow-up data

Contacts

No contact information available.

HER2 Testing and Treatment for High-grade Ovarian Cancer

Ready to participate?

You may be able to join if

You may not be able to join if

Think this trial could be right for you?